Daniel Del Conde – CEO, Grupo Somar, Quifa Mexico & Quifa do Brazil
Four years ago, Daniel Del Conde left a career in multinational pharma to become the CEO of regional player Grupo Somar. He walks us through the company’s activities – private…
Innovare R&D was founded in 1995 with the scope of a CMO in the field of generic products, mostly synthetic hormones. Despite the fact that the generic unit is ongoing, at a smaller size, since 2008 through a completely new Board of Directors and shareholders, the Company´s focus of business has been driven into novel, high specialty products in the Hematology, Immunology, and Infectious Disease fields.
Contact details
Innovare R&D
Paseo de la Reforma 2620 PH 4
Col. Lomas Altas
CP 11950, México DF
MEXICO
Tel: +52 (55) 5273 6055
Website: http://www.innovare-rd.com.mx/
Four years ago, Daniel Del Conde left a career in multinational pharma to become the CEO of regional player Grupo Somar. He walks us through the company’s activities – private…
While the COVID-19 pandemic revealed vulnerabilities that sent many organizations looking for ways to bring supply chains closer to home, geopolitical tensions have also encouraged companies to avoid dependence on…
In a move to address medicine shortages Mexico’s outgoing president Andrés Manuel López Obrador last year launched a Super Pharmacy, or “Megafarmacia del Bienestar,” dubbed the largest medicine stockpile n…
The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues,…
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
See our Cookie Privacy Policy Here
